Care strategy & key drivers

Key drivers of pathology

Atherosclerotic cardiovascular disease (ASCVD) is fundamentally a disease of cumulative ApoB-particle exposure to a vulnerable arterial wall, modified by vascular inflammation, endothelial dysfunction, oxidative stress, and — for a sizeable subset — genetically elevated lipoprotein(a). Hypertension contributes both as an independent vascular stressor and as an accelerator of plaque burden, mediated by sympathetic activation, RAAS dysregulation, salt-sensitivity, loss of endothelial nitric oxide bioavailability, and arterial stiffening.

Insulin resistance, MASLD, and visceral adiposity amplify all of these mechanisms simultaneously and remodel the lipid profile toward small, dense, atherogenic particles, which is why CV risk in metabolically unhealthy patients is consistently underestimated by LDL-C-only models. Lp(a) — largely genetically determined — is an independent, unmodifiable-by-lifestyle risk amplifier that warrants more aggressive ApoB lowering when elevated.

Care strategy — beyond LDL-C

Mapping interventions to drivers

Each lever in this protocol is selected for a specific mechanism so they can be combined purposefully rather than stacked indiscriminately.

• Mediterranean and DASH patterns combine direct ApoB lowering (reduced saturated fat, increased soluble fibre) with anti-inflammatory polyphenol load and vasodilatory potassium and dietary nitrate intake.
• Soluble fibre 7–10 g/day binds bile acids, forcing hepatic LDL-receptor upregulation.
• Phytosterols competitively inhibit cholesterol absorption for an additional ~10% LDL reduction additive to dietary measures.
• High-EPA omega-3 lowers triglycerides, stabilizes plaque, and exerts modest BP and anti-inflammatory effects.
• Magnesium glycinate addresses common subclinical deficiency and supports nocturnal BP and sleep quality.
• L-citrulline / beetroot products restore NO bioavailability and endothelial function.
• Isometric handgrip training delivers the largest non-pharmacologic systolic effect documented in meta-analyses.
• Aerobic and resistance training improve endothelial function, BP, and the underlying metabolic milieu.

Statin-intolerant patients can often achieve clinically meaningful ApoB reduction by stacking phytosterols, soluble fibre, and EPA — ideally alongside dietary change rather than as a substitute for it.